Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Tangible benefit for FLT3-ITD R/R AML on quizartinib

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the characterization of response and transfusion independence in relapsed/refractory FLT3-ITD mutated acute myeloid leukemia (AML) patients treated with quizartinib or salvage chemotherapy on the QuANTUM-R trial (NCT02039726). This revealed a tangible benefit from quizartinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.